IN8bio, Inc. (INAB)

NASDAQ: INAB · Real-Time Price · USD

0.322

+0.005 (1.42%)

At close: Nov 20, 2024, 4:00 PM

0.346

+0.024 (7.62%)

Pre-market: Nov 21, 2024, 6:00 AM EST

IN8bio Employees

IN8bio had 31 employees as of December 31, 2023. The number of employees increased by 5 or 19.23% compared to the previous year.

Employees

31

Change (1Y)

5

Growth (1Y)

19.23%

Revenue / Employee

n/a

Profits / Employee

-$1,028,226

Market Cap

23.30M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2023	31	5	19.23%
Dec 31, 2022	26	7	36.84%
Dec 31, 2021	19	5	35.71%
Dec 31, 2020	14	-	-

Related Stocks

Company Name	Employees
Bolt Biotherapeutics	100
BioXcel Therapeutics	74
PolyPid	62
Femasys	34
Chemomab Therapeutics	20
Tempest Therapeutics	17
NeuroOne Medical Technologies	16
AEON Biopharma	10

Employee Rankings

INAB News

8 days ago - IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - GlobeNewsWire
2 months ago - IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia - GlobeNewsWire
3 months ago - IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
3 months ago - IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100 - GlobeNewsWire
5 months ago - IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference - GlobeNewsWire
5 months ago - IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 - GlobeNewsWire
6 months ago - IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting - GlobeNewsWire
6 months ago - IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024 - GlobeNewsWire